| P50 | author | Delia Preti | Q56479662 |
| P2093 | author name string | Pier Giovanni Baraldi | |
| | Romeo Romagnoli | |
| | Katia Varani | |
| | Pier Andrea Borea | |
| | Mojgan Aghazadeh Tabrizi | |
| | Francesca Fruttarolo | |
| | Andrea Bovero | |
| | Barbara Avitabile | |
| P2860 | cites work | Molecular cloning and characterization of the human A3 adenosine receptor | Q24564442 |
| | A physiological role of the adenosine A 3 receptor: Sustained cardioprotection | Q24650457 |
| | Crystal structure of rhodopsin: A G protein-coupled receptor | Q27625972 |
| | Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 |
| | 7-Substituted 5-Amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2AAdenosine Receptor Antagonists: A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility | Q28213414 |
| | Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line | Q28363730 |
| | Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists | Q28370203 |
| | Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors | Q28372041 |
| | LIGAND: A versatile computerized approach for characterization of ligand-binding systems | Q29547346 |
| | 8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. | Q32049468 |
| | A(2A) adenosine receptors in human peripheral blood cells | Q33849871 |
| | A(3) adenosine receptor ligands: history and perspectives | Q33866688 |
| | Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications | Q33939663 |
| | Structure and function of adenosine receptors and their genes. | Q34101838 |
| | Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. | Q34156776 |
| | 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs | Q34169391 |
| | A3-adenosine receptors: design of selective ligands and therapeutic prospects | Q34204046 |
| | Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats | Q34485914 |
| | Adenosine A3 receptors: novel ligands and paradoxical effects | Q35171034 |
| | The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2a selective adenosine receptor antagonist | Q35872902 |
| | Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding | Q35873630 |
| | Adenosine A3 receptor stimulation and cerebral ischemia | Q36185246 |
| | 8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo | Q36308893 |
| | Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects | Q36311423 |
| | Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist | Q40712319 |
| | Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies | Q40787416 |
| | Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors | Q40975392 |
| | Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype | Q41158990 |
| | Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia | Q41624006 |
| | 3H‐SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes | Q41961480 |
| | Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes | Q42196443 |
| | Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. | Q42545166 |
| | A role for mast cells in adenosine A3 receptor‐mediated hypotension in the rat | Q42708149 |
| | Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists | Q42812168 |
| | Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]‐SCH 58261 binding | Q43176977 |
| | A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study | Q43865622 |
| | Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists | Q43879029 |
| | Binding thermodynamics at the human A(3) adenosine receptor | Q43883966 |
| | (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists | Q46418896 |
| | Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. | Q47829073 |
| | Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2A Adenosine Receptor Antagonists | Q47986048 |
| | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys | Q48208543 |
| | Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists | Q48458817 |
| | Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists | Q48561677 |
| | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists | Q49097634 |
| | Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors | Q49121544 |
| | Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists: Influence of the Chain at the N8Pyrazole Nitrogen | Q56979856 |
| | Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases | Q57405388 |
| | Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys | Q64905504 |
| | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists | Q73223426 |
| | 4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo [4,3-alpha]-quinoxalin-1-one: a new A2A adenosine receptor antagonist with high selectivity versus A1 receptors | Q77417378 |
| | A3 Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists | Q91750595 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 367-382 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | European Journal of Medicinal Chemistry | Q3008624 |
| P1476 | title | Recent developments in the field of A2A and A3 adenosine receptor antagonists | |
| P478 | volume | 38 | |